Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy
- 1 January 2013
- journal article
- review article
- Published by Japanese Society for the Study of Xenobiotics in Drug Metabolism and Pharmacokinetics
- Vol. 28 (1) , 38-43
Abstract
The teratogenic effects of thalidomide have been studied for more than 50 years. However, there have been few studies of the pharmacokinetic changes occurring during thalidomide therapy. Thalidomide was originally developed as a sedative. However, thalidomide induces multiple birth defects when used in pregnant women. Thalidomide is now used in the treatment of multiple myeloma (MM) and erythema nodosum leprosum (ENL) in Japan. Rational use of thalidomide is problematic due to a lack of basic research regarding its mechanism of action and serum concentration/effect relationships. There are a number of hypotheses for pharmacokinetic changes in thalidomide therapy. Genetic factors including single nucleotide polymorphisms (SNPs) that change cytochrome P450 (CYP) activity and epigenetic regulation that modifies CYP expression levels may contribute to the changes in pharmacokinetics and adverse drug reactions (ADRs) of thalidomide. Environmental factors include the pharmacological context of drug-drug interactions and the physiological context of liver diseases. Liver and kidney diseases do not play important roles in pharmacokinetic changes or ADRs in thalidomide therapy. To date, most research has focused on teratogenic activity, while the impact of polymorphisms in genes encoding drug metabolic enzymes and drug-drug interactions could mediate ADRs. Here, we discuss clinical evidence of pharmacokinetic changes in thalidomide therapy.Keywords
This publication has 53 references indexed in Scilit:
- Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-GlycoproteinJournal of Clinical Oncology, 2011
- The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patientsCancer Chemotherapy and Pharmacology, 2011
- No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple MyelomaBMC Cancer, 2010
- Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazolesBritish Journal of Clinical Pharmacology, 2010
- Drug Interactions of Thalidomide with Midazolam and Cyclosporine A: Heterotropic Cooperativity of Human Cytochrome P450 3A5Drug Metabolism and Disposition, 2009
- Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotypingBlood, 2008
- Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinomaCancer Chemotherapy and Pharmacology, 2006
- Clinical Pharmacokinetics of ThalidomideClinical Pharmacokinetics, 2004
- Current Therapy of Multiple Myeloma.Internal Medicine, 2002
- (S)-Form of .ALPHA.-Methyl-N(.ALPHA.)-phthalimidoglutarimide, but Not Its (R)-Form, Enhanced Phorbol Ester-Induced Tumor Necrosis Factor-.ALPHA. Production by Human Leukemia Cell HL-60: Implication of Optical Resolution of Thalidomidal Effects.Chemical and Pharmaceutical Bulletin, 1994